The United Kingdom and the United States have finalized a significant commercial pact that will preserve zero duties on British drug shipments being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the NHS. This move guarantees that tariffs on these crucial products will stay at zero for a duration of three years.
This development follows recent threats to significantly raise import taxes on patented pharmaceutical products, with potential rates discussed as high as one hundred percent.
"This agreement between the UK reinforces the global environment for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," a release declared.
Trade Impact
Medicines represent one of the Britain's biggest export categories to the US, which is easily the biggest market for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period prior to last September, the UK exported medicines worth over eleven billion pounds to the US. This value accounted for a significant portion of all goods exports in that period.
"This guarantee protects work, stimulates investment and paves the way for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Detailed NHS Changes
The deal entails several key changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
The pact follows a long-running row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were heightened by assertions that US consumers were charged a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
